These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39026680)

  • 1. Nephrotoxicity of targeted therapy used to treat lung cancer.
    Li Q; Lin J; Hao G; Xie A; Liu S; Tang B
    Front Immunol; 2024; 15():1369118. PubMed ID: 39026680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.
    Marjanski T; Dziedzic R; Kowalczyk A; Rzyman W
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
    Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
    Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized targeted therapy for lung cancer.
    Wu K; House L; Liu W; Cho WCS
    Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
    Indini A; Rijavec E; Ghidini M; Bareggi C; Gambini D; Galassi B; Antonelli P; Bettio G; Di Nubila C; Grossi F
    Expert Opin Pharmacother; 2020 Jun; 21(8):931-940. PubMed ID: 32162559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular and orbital side effects of ALK inhibitors: a review article.
    Chelala E; Hoyek S; Arej N; Kattan J; Kourie HR; Baakliny J; Antoun J
    Future Oncol; 2019 Jun; 15(16):1939-1945. PubMed ID: 31140869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.
    Tabchi S; Kourie HR; Kattan J
    Invest New Drugs; 2016 Dec; 34(6):794-796. PubMed ID: 27562868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
    De Mello RA; Liu DJ; Aguiar PN; Tadokoro H
    Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular oncology of lung cancer.
    Toyooka S; Mitsudomi T; Soh J; Aokage K; Yamane M; Oto T; Kiura K; Miyoshi S
    Gen Thorac Cardiovasc Surg; 2011 Aug; 59(8):527-37. PubMed ID: 21850578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
    Wrona A; Dziadziuszko R; Jassem J
    Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
    Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
    J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.